Rocket One's Hoth Therapeutics Reports Strong HT-001 Efficacy Results, Ends Phase 2a Early and Plans to Pursue Phase 3 to Bring Treatment to Cancer Patients

What happened: Rocket One Inc. (Nasdaq: RKTO) said its subsidiary Hoth Therapeutics ended the Phase 2a trial of HT-001 early after strong interim efficacy results and is preparing to seek FDA feedback on a potential Phase 3 program. Key numbers: Interim results announced Nov. 3, 2026. Why it matters: Hoth plans to discuss a potential pivotal study design, endpoints, patient population, and manufacturing readiness with the FDA. Phase 3 initiation depends on regulatory feedback and completion of required development activities.

Rocket One Inc. (Nasdaq: RKTO) said its subsidiary Hoth Therapeutics ended the Phase 2a trial of HT-001 early after strong interim efficacy results and is preparing to seek FDA feedback on a potential Phase 3 program.

Hoth plans to discuss a potential pivotal study design, endpoints, patient population, and manufacturing readiness with the FDA. Phase 3 initiation depends on regulatory feedback and completion of required development activities.